Design and evaluation of naphthol- and carbazole-containing fluorescent σ ligands as potential probes for receptor binding studies

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4648-4655

  Ferorelli, Savina ^a   Abate, Carmen ^a   Colabufo, Nicola Antonio ^a   Niso, Mauro ^a   Inglese, Carmela ^a   Berardi, Francesco ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOHEXYL 4 (3 NAPHTHYLPROPYL)PIPERAZINE DERIVATIVE; 1 CYCLOHEXYL 4 [3 (6 HYDROXYNAPHTHALEN 1 YL)PROPYL]PIPERAZINE; 3,3 DIMETHYL 1 (3 NAPHTHYLPROPYL)PIPERIDINE DERIVATIVE; CARBAZOLE DERIVATIVE; FLUORESCENT DYE; NAPHTHOL DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE; GUINEA PIG; MALE; NONHUMAN; RADIOASSAY; RAT; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ANIMALS; CARBAZOLES; COMPETITIVE BIDDING; FLUORESCENT DYES; LIGANDS; LIVER; NAPHTHOLS; PIPERAZINES; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34648830947     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070373b     Document Type: Article

References (47)

1. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T.-P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
2. Su, T. S.; Hayashi, T. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr. Med. Chem. 2003, 10, 2073-2080.
3. Guitart, X.; Codony, X.; Monroy, X. Sigma receptors: Biology and therapeutic potential. Psychopharmacology 2004, 174, 301-319.
4. Kekuda, R.; Prasad, P. D.; Fei, Y.-J.; Leibach, F. H.; Ganapathy, V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Byochem. Biophys. Res. Commun. 1996, 229, 553-558.
5. Moebius, F. F.; Striessnig, J.; Glossmann, H. The mysteries of sigma receptors: New family members reveal a role in cholesterol synthesis. Trends Pharmacol. Sci. 1997, 18, 67-70.
6. Bowen, W. D. Sigma receptors: Recent advances and new clinical potentials. Pharm. Acta Helv. 2000, 74, 211-218.
7. Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apopototic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62, 313-322.
8. Hayashi, T.; Su, T.-P. Regulation ankyrin dynamics; roles of sigma-1 receptors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 491-496.
9. 1 antagonist receptor inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol. Cancer Ther. 2006, 5, 1807-1816.
10. 2 receptor a histone binding protein? J. Med. Chem. 2006, 49, 4153-4158.
11. Caveliers, V.; Everaert, H.; Lahoutte, T.; Dierickx, L. O.; John, G. S.; Bossuyt, A. Labelled sigma receptor ligands: Can their role in neurology and oncology be extended? Eur. J. Nucl. Med. 2001, 28, 133-135.
12. Colabufo, N. A.; Berardi, F.; Contino, M.; Ferorelli, S.; Niso, M.; Perrone, R.; Pagliarulo, A.; Saponaro, P.; Pagliarulo, V. Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Lett. 2006, 237, 83-88.
13. 2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 2006, 59, 350-358.
14. Nakazato, A.; Otha, K.; Sekiguchi, Y.; Okuyama, S.; Chaki, S.; Kawashima, Y.; Hatayama, K. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine σ ligands as potential antipsychotic drugs. J. Med. Chem. 1999, 42, 1076-1087.
15. 1 receptor binding. J. Med. Chem. 1994, 37, 1214-1219.
16. Ablordeppey, S. Y.; Fischer, J. B.; Law, H.; Glennon, R. A. Probing the proposed phenyl-A region of the sigma-1 receptor. Bioorg. Med. Chem. 2002, 10, 2759-2765.
17. Ablordeppey, S. Y; Fischer, J. B.; Glennon, R. A. Is a nitrogen atom an important pharmaphoric element in sigma ligand binding? Bioorg. Med. Chem. 2000, 8, 2105-2111.
18. 1 receptor. J. Med. Chem. 2005, 48, 8237-8244.
19. 2 binding site. 1. 3-(ω-Aminoalkyl)-1H-indoles. J. Med. Chem. 1995, 38, 1998-2008.
20. Ostenfeld, M. S.; Fehrenbacher, N.; Hover-Hansen, M.; Thomsen, C.; Farkas, T.; Jaattela, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005, 65, 8975-8983.
21. 1A receptor ligands: ω-(Tetralin-1-yl)-n-alkylamine derivatives. J. Med. Chem. 1996, 39, 176-182.
22. Cassano, G.; Gasparre, G.; Contino, M.; Niso, M.; Berardi, F.; Perrone, R.; Colabufo, N. A. The sigma-2 receptor agonist PB28 inhibits calcium release from endoplasmic reticulum of SK-N-SH neuroblastoma cells. Cell Calcium 2006, 40, 23-28.
23. 2 ligands activity in the isolated guinea pig bladder. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 368, 106-112.
24. Daly, C. J.; McGrath, J. C. Fluorescent ligands, antibodies, and proteins for the study of receptors. Pharmacolol. Ther. 2003, 100, 101-118.
25. McGrath, J. C.; Arrabis, S.; Daly, C. J. Fluorescent ligands for the study of receptors. Trends Pharmacol. Sci. 1996, 17, 393-399.
26. 2 receptor ligands. Bioorg. Med. Chem. 2006, 14, 6988-6997.
27. McGrath, J. C.; Daly, C. J. Do fluorescent drugs show you more than you wanted to know? Br. J. Pharmacol. 2003, 139, 187-189.
28. Sartor, G.; Pagani, R.; Ferrari, E.; Sorbi, R. T.; Cavaggioni, A.; Cavatorta, P.; Spisni, A. Determining the binding capability of the mouse major urinary proteins using 2-naphthol as a fluorescent probe. Anal. Biochem. 2001, 292, 69-75.
29. Hu, D.; Crouxté-Barghorn, C.; Feuillade, M.; Carré, C. Fluorescence study of the sol-gel process in hybrid precursors: Evidence of concentration fluctuations at the local scale. J. Phys. Chem. B 2005, 109, 15214-15220.
30. Nishikiori, H.; Tanaka, N.; Kubota, S.; Endo, M.; Fujii, T. In situ characterization of surface physicochemical properties of carbon nanofibers using 1-naphthol as a fluorescent probe. Chem. Phys. Lett. 2004, 390, 289-393.
31. Kubota, S.; Nishikiori, H.; Tanaka, N.; Endo, M.; Fujii, T. Dispersion of acid-treated carbon nanofibers into gel matrices prepared by the sol-gel method. J. Phys. Chem. B 2005, 109, 23170-23174.
32. 1 and EBP sites. Bioorg Med. Chem. 2001, 9, 1325-1335.
33. 2 activity. J. Med. Chem. 2004, 47, 2308-2317.
34. Ho, C.; Slater, S. J.; Stubbs, C. D. The use of the fluorescence properties of indoloearbazole analogs of adenosine triphosphate as probes of the activating conformational change in protein kinase C. J. Photochem. Photobiol. A: Chem. 2001, 142, 163-168.
35. Benten, H.; Ohkita, H.; Ito, S.; Yamamoto, M.; Tohda, Y.; Tani, K. Evaluation of local polarity of polymer solids by a rigid fluorescent probe of carbazole-terephthalate cyclophane. Polymer 2004, 45, 2831-2836.
36. Kim, T. W.; Yoon, H. Y.; Park, J.; Kwon, O.; Jang, D.; Hong, J. Molecular tripods showing fluorescence enhancement upon binding to streptavidin. Org. Lett. 2005, 7, 111-114.
37. 1A/D-2 activity of a new model of arylpiperazines: 1-Aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n- propyl]piperazines. 1. Synthesis and structure-activity relationships. J. Med. Chem. 1994, 37, 99-104.
38. Mastrangelo, J. C.; Conger, B. M.; Chen, S. H. Novel glass forming organic materials. 2. Structure and fluorescence of pyrene- and carbazole-containing cyclohexane, bycyclooctene, and adamantine. Chem. Mater. 1997, 9, 227-232.
39. Guan, J.; Kyle, D. E.; Gerena, L.; Zhang, Q.; Milhous, W. K.; Lin, A. J. Design, synthesis, and evaluation of new chemosensitizers in multi-drug-resistant Plasmodium falciparum. J. Med. Chem. 2002, 45, 2741-2748.
40. Bu-Hoi, NG. PH.; Royer, R. Potential nitrogen-heterocycle carcinogens. XI. Substitution reactions of N-alkylcarbazoles. J. Org. Chem. 1951, 16, 1198-1205.
41. ClogP, version 4.0 for Windows; BioByte Corp., Claremont, CA.
42. Prism Software, version 3.0 for Windows (1998); GraphPad Software, Inc., San Diego, CA.
43. Velapoldi, R. A.; Tønnesen, H. H. Corrected emission spectra and quantum yields for a series of fluorescent compounds in the visible spectra region. J. Fluoresc. 2004, 14, 465-472.
44. Tomoda, H.; Hirano, T.; Saito, S.; Mutai, T.; Araki, K. Sustituent effects on fluorescent properties of imidazo[1,2-a]pyridine-based compounds. Bull. Chem. Soc. Jpn. 1999, 72, 1327-1334.
45. 1 antagonists in tumour cell lines. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 370, 106-113.
46. Matsumoto, R. R.; Bowen, W. D.; Tom, M. A.; Truong, D. D.; De Costa, B. R. Characterization of two novel sigma receptor ligands: Antidystonic effects in rats suggest sigma receptor antagonism. Eur. J. Pharmacol. 2005, 280, 301-310.
47. 3H]ifenprodil. Mol. Pharmacol. 1998, 54, 591-598.